Mepolizumab effectiveness for patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps in Italy (MEPOREAL): a real-life, multicentre, phase 4 trial
Elsevier ·
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
Mepolizumab effectiveness for patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps in Italy (MEPOREAL): a real-life, multicentre, phase 4 trial. // The Lancet Respiratory Medicine. – URL: https://www.sciencedirect.com/science/article/pii/S2213260026001979?dgcid=rss_sd_all
Mepolizumab effectiveness for patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps in Italy (MEPOREAL): a real-life, multicentre, phase 4 trial. The Lancet Respiratory Medicine. https://www.sciencedirect.com/science/article/pii/S2213260026001979?dgcid=rss_sd_all
“Mepolizumab effectiveness for patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps in Italy (MEPOREAL): a real-life, multicentre, phase 4 trial.” The Lancet Respiratory Medicine.
@article{article32486,
title = {Mepolizumab effectiveness for patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps in Italy (MEPOREAL): a real-life, multicentre, phase 4 trial},
journal = {The Lancet Respiratory Medicine},
url = {https://www.sciencedirect.com/science/article/pii/S2213260026001979?dgcid=rss_sd_all}
}